User profiles for Ton N. Schumacher
Ton NM SchumacherThe Netherlands Cancer Institute, Third Rock Ventures Verified email at nki.nl Cited by 82789 |
Neoantigens in cancer immunotherapy
TN Schumacher, RD Schreiber - Science, 2015 - science.org
The clinical relevance of T cells in the control of a diverse set of human cancers is now beyond
doubt. However, the nature of the antigens that allow the immune system to distinguish …
doubt. However, the nature of the antigens that allow the immune system to distinguish …
[PDF][PDF] Regulation and function of the PD-L1 checkpoint
Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human cancers.
Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor immunity by …
Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor immunity by …
Tertiary lymphoid structures in cancer
TN Schumacher, DS Thommen - Science, 2022 - science.org
BACKGROUND Tertiary lymphoid structures (TLSs) are organized aggregates of immune
cells that form postnatally in nonlymphoid tissues. TLSs are not found under physiological …
cells that form postnatally in nonlymphoid tissues. TLSs are not found under physiological …
Signatures of mutational processes in human cancer
All cancers are caused by somatic mutations; however, understanding of the biological
processes generating these mutations is limited. The catalogue of somatic mutations from a …
processes generating these mutations is limited. The catalogue of somatic mutations from a …
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Immune checkpoint inhibitors, which unleash a patient’s own T cells to kill tumors, are
revolutionizing cancer treatment. To unravel the genomic determinants of response to this therapy, …
revolutionizing cancer treatment. To unravel the genomic determinants of response to this therapy, …
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
The immune system influences the fate of developing cancers by not only functioning as a
tumour promoter that facilitates cellular transformation, promotes tumour growth and sculpts …
tumour promoter that facilitates cellular transformation, promotes tumour growth and sculpts …
The human cell atlas
10.7554/eLife.27041.001 The recent advent of methods for high-throughput single-cell
molecular profiling has catalyzed a growing sense in the scientific community that the time is ripe …
molecular profiling has catalyzed a growing sense in the scientific community that the time is ripe …
B cells and tertiary lymphoid structures promote immunotherapy response
…, EA Rozeman, D Peeper, CU Blank, TN Schumacher… - Nature, 2020 - nature.com
Abstract Treatment with immune checkpoint blockade (ICB) has revolutionized cancer therapy.
Until now, predictive biomarkers 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 – 10 and strategies to augment …
Until now, predictive biomarkers 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 – 10 and strategies to augment …
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
…, M Kok, ME Van Leerdam, TN Schumacher… - Nature medicine, 2020 - nature.com
PD-1 plus CTLA-4 blockade is highly effective in advanced-stage, mismatch repair (MMR)-deficient
(dMMR) colorectal cancers, yet not in MMR-proficient (pMMR) tumors. We postulated …
(dMMR) colorectal cancers, yet not in MMR-proficient (pMMR) tumors. We postulated …
Defining 'T cell exhaustion'
…, NP Restifo, A Schietinger, TN Schumacher… - Nature Reviews …, 2019 - nature.com
… Blank and Ton N. Schumacher. Instead, we would rather argue that the analysis of T cells
in human and mouse tumours by single-cell sequencing and functional assays has provided …
in human and mouse tumours by single-cell sequencing and functional assays has provided …